American patients often pay far more for prescription drugs than their peers abroad – so much more, in fact, that U.S. consumers are effectively subsidizing cheaper medicines for Canada, Europe, and other countries. This pricing structure acts as a hidden form of foreign aid, one not approved by Congress but extracted through sky-high domestic drug prices. On average, Americans pay 2 to 3 times what patients in other developed nations pay for the same medications.
Advertisement
Drug companies often justify U.S. price premiums by pointing to research and development costs and the need to fund innovation. Indeed, America’s outsize spending has helped it become a world leader in new drug development, accounting for a disproportionate share of global pharmaceutical sales.
But this system also means Americans shoulder an unfair share of the cost burden. Policies in other countries force drugs to be sold below what a free market might dictate, and drugmakers make up the difference by charging Americans more.
It is “well-known that Americans unfairly subsidize biopharmaceutical innovation for the world,” as one policy analysis noted, with the U.S. paying significantly more for the same medications than nations with government price controls.
A 2015 Reuters analysis found U.S. prices for the 20 top-selling drugs were triple those in Britain, making America “by far the most profitable market” for pharmaceutical companies and “leading to complaints that Americans are effectively subsidizing health systems elsewhere.”
In other words, U.S. drug pricing has become a de facto global subsidy, with American wallets funding discounts abroad.
Price Disparities: Americans Pay More so Others Can Pay Less
Pharmaceutical manufacturers prioritize high prices in the U.S. while accepting steep discounts in secondary markets like Canada and Europe. Other governments leverage bulk purchasing and price controls to negotiate dramatically lower rates than what Americans are charged. For example, Canada directly regulates drug prices and most European countries have government-run health systems that bargain hard with drugmakers. Because the U.S. largely leaves pricing to the market, companies can charge whatever the traffic will bear – and they do. The result is a staggering price gap: U.S. prescription drug prices average about 2.78 times higher than those in 33 other nations (and over 4 times higher for brand-name drugs).
Over the past 15 years, foreign “free-riding” has only increased – prices for many top drugs in Europe fell from about 51% of U.S. prices to just 32% by 2017, leaving Americans to pay a greater share of R&D costs
In essence, other countries’ healthcare systems stay sustainable and affordable because American patients bankroll the difference
This implicit cross-subsidy may benefit patients in London or Toronto, but it leaves patients in Los Angeles and Tampa with unreasonably high bills.
Advertisement
Join the conversation as a VIP Member